Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: linzagolix choline, gonadorelin, relugolix +29 | 1.00 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 1 stopped | 0.73 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9947
Sealed predictions
- GNRHR in dopamine neurons, braak-0.30 (p 0.428) → +0.10 (p 0.803)receipt 9954
Swarm cases
receipt 9954: GNRHR in dopamine neurons, braak
- power
- full sample +0.02 (p 0.942, n 18), 95% CI -0.45 to +0.48. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.976, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.06 (p 0.814, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.15, sign flips 7; without severely affected donors +0.02 (p 0.942, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GNRHR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts